Affordable Access

Publisher Website

7157 Duodenoscope-assisted cholangiopancreatoscopy (dacp) achieves technical aims and impacts on biliary and pancreatic disease management.

Gastrointestinal Endoscopy
DOI: 10.1016/s0016-5107(00)14828-x
  • Medicine


Background: DACP, as an adjunct to ERCP allows for direct visualization of the biliary duct and pancreatic duct.We aim to assess the technical feasibility of DACP for a variety of clinical indications and to determine its impact on disease management. Methods: 94 consecutive DACP examinations were performed in 57 patients with 3 groups of disorders, choledocholithiasis (CDL), biliary strictures(BS) and pancreatic disease(PD), age range (24 to 91 years; mean 69). All DACPs were performed using the Pentax FCP-8P or 9P. Data pertaining to indication, technical success, and clinical impact of DACP on disease management were collected and analyzed using cMore endoscopic database. Results: CDL (n=53, 27 pts ) Indications included stone fragmentation using EHL (n=34), evaluation of biliary tree post-stone removal (n=14), distinction between stone and stricture, evaluation of biliary tree for stones despite normal cholangiogram (n=5). Technical success was achieved in 29/53 DACPs. The 24/53 failures represent partial fragmentation of stones with EHL in 8 patients with extensive disease. Use of DACP resulted in complete removal of biliary tree stones in 10/34 examinations (10 patients) and demonstrated the presence of stones in 4 patients with normal post-interventional cholangiograms. Furthermore DACP helped to confirm the absence of stones after removal by basket or balloon in 11/12 patients. BS (n=33, 23 pts) Indications included evaluation of stricture(n=21) or Wallstent occlusion (n=4), and monitoring of cholangiocarcinoma progression in a single patient (n=7). Technical success was achieved in 29/33 cases. DACP assisted in confirming or clarifying the nature of a stricture in 16/29 cases, and in stent management in 20/29 cases. PD (n=7) Indications included evaluation of pancreatic duct obstruction in chronic pancreatitis (n=4) and malignancy (n=1), and evaluation of PD for IPMT (n=2). An additional use of DACP was in the evaluation of hemobilia (n=1) where no source was seen. There were no complications reported with the use of DACP. Conclusion: DACP is technically feasible in the management of pancreatico-biliary diseases. Lack of complete technical success in the use of EHL to fragment stones is due to extensive stone disease in a limited number of patients. Otherwise DACP impacts on the management of complicated biliary tract disease by clarifying cholangiograms, assisting in EHL stone fragmentation, and guiding stenting and surgical management.

There are no comments yet on this publication. Be the first to share your thoughts.